Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Inventory (2017 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Inventory for 9 consecutive years, with $52.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Inventory rose 15.56% to $52.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $52.0 million, a 15.56% increase, with the full-year FY2025 number at $52.0 million, up 15.56% from a year prior.
  • Inventory was $52.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $46.5 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $52.0 million in Q4 2025 to a low of $15.1 million in Q2 2021.
  • A 5-year average of $32.5 million and a median of $32.9 million in 2023 define the central range for Inventory.
  • Peak YoY movement for Inventory: increased 5.08% in 2021, then skyrocketed 45.55% in 2023.
  • Ultragenyx Pharmaceutical's Inventory stood at $15.2 million in 2021, then skyrocketed by 76.2% to $26.8 million in 2022, then rose by 26.91% to $34.0 million in 2023, then skyrocketed by 32.47% to $45.0 million in 2024, then rose by 15.56% to $52.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Inventory are $52.0 million (Q4 2025), $46.5 million (Q2 2025), and $46.0 million (Q1 2025).